What exactly did BTIG do on March 03, 2026 for SOPH analyst rating?

BTIG reaffirmed a **Buy** rating for SOPHiA GENETICS S.A. (SOPH) on March 03, 2026 at 02:23 PM. The note did not update a price target and showed **0.0%** immediate price change in the published summary.

Does the BTIG note change the SOPH price target?

No. BTIG’s March 03, 2026 note maintained the Buy rating but did not publish a revised SOPH price target in the summary available through StreetInsider.

How should investors use a maintained Buy rating from BTIG?

Treat a maintained Buy as confirmation of analyst conviction rather than a new catalyst. Combine it with the Q4 2025 earnings details and the Meyka AI grade of B to assess risk, expected upside, and timing.

How current is analyst coverage for SOPH beyond this note?

This output records only BTIG’s March 03, 2026 action. Investors should check additional sources and follow-up notes for broader coverage before changing position sizes.

Analyst Ratings

BTIG Maintains Buy on SOPHiA GENETICS S.A. (SOPH) March 03, 2026

ByHuzaifa Zahoor March 4, 2026March 4, 2026

BTIG maintained its Buy rating on SOPHiA GENETICS S.A. (SOPH) on March 03, 2026, giving investors continuity on analyst guidance and creating a clear SOPH analyst rating update. The March 03, 2026 note was recorded at 02:23 PM and showed no immediate price reaction (0.0%) when published. Market cap stands at $278,172,938, and BTIG did not revise a public price target in the published bulletin. We link the analyst action to the company’s recent earnings commentary and provide context for investors.